Ignite Creation Date:
2025-12-24 @ 10:20 PM
Ignite Modification Date:
2025-12-29 @ 2:54 AM
Study NCT ID:
NCT05025735
Status:
UNKNOWN
Last Update Posted:
2021-10-19
First Post:
2021-06-26
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
Sponsor:
Saint Luke's Health System
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-08-25
Start Date Type:
ACTUAL
Primary Completion Date:
2022-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-07
Completion Date Type:
ESTIMATED
First Submit Date:
2021-06-26
First Submit QC Date:
None
Study First Post Date:
2021-08-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-10-14
Last Update Post Date:
2021-10-19
Last Update Post Date Type:
ACTUAL